Drug Development

Clinical Trials Weight Loss Drugs Obesity Treatments Clinical Research Market Competition Oncology Licensing Agreements Market Trends Artificial Intelligence Regulatory Affairs

3 ARTICLES

last wk.

AlzeCure Out‑Licenses Preclinical Alzheimer’s Candidate ACD680 to Eli Lilly

The deal gives Lilly global development and commercial rights with a $10 million upfront payment plus milestone terms that could push value above $1 billion pending Swedish foreign investment clearance.

9 ARTICLES

last wk.

Drug Development

AlzeCure Out‑Licenses Preclinical Alzheimer’s Candidate ACD680 to Eli Lilly

Roche and Nurix Strike $700M Deal to Co‑Develop Oral BTK Degrader Bexobrutideg

Zealand Pharma Shares Tumble After Survodutide Phase III Shows High Dropouts

Lilly Secures Global Rights to Hanmi’s Sonefpeglutide

Pfizer and Innovent Strike Up to $10.5 Billion Oncology Collaboration

One Infusion Cuts LDL by Up to 62% in Early Gene‑Editing Trial

Novo Nordisk Narrows Gap With Lilly as Wegovy Pill Leads Early Oral Sales

Bristol Myers Squibb to Deploy Anthropic’s Claude Across Global Operations

Bristol Myers and Hengrui Ink Up to $15.2 Billion Drug Discovery Alliance

Novo Nordisk Lifts 2026 Outlook as Wegovy Pill Powers Big Q1 Beat

Never miss stories about

Drug Development

Pfizer Settles With Three Generics to Keep Vyndamax Exclusive Until 2031

AstraZeneca Revives UK Plans With £300 Million for Cambridge and Macclesfield

FDA Launches First Real-Time Clinical Trial Pilot With AstraZeneca and Amgen

Lilly and Profluent Strike AI Gene-Editing Pact Worth Up to $2.25 Billion

Boehringer Ingelheim to Invest £150 Million in London AI Drug Discovery Centre

OpenAI Launches GPT-Rosalind, a Biology-Tuned AI for Drug Discovery

Roche Starts Placebo-Controlled Phase 3 Trial of Elevidys to Pursue EU Approval

Novo Nordisk Partners With OpenAI to Speed Drug Development and Operations

Allogene Soars on Early ALPHA3 Readout Showing Strong MRD Edge and Clean Safety

IDEAYA Combo Doubles Progression-Free Survival in Uveal Melanoma Trial

Never miss stories about

Drug Development